MedTrace Logo

Roflumilast to Treat Cognitive Sequela After Stroke

NCT04854811 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-01-17

No results posted yet for this study

Summary

The aim of the current project is to validate the effects of chronic rolflumilast treatment (12 weeks) on cognitive functions (i.e. episodic memory) by means of behavioral tasks, in people suffering from cognitive impairments at least 1 year after stroke. Secondarily, the effects of roflumilast on daily activities and well-being will be assessed.

Conditions

  • Cerebrovascular Disorders
  • Memory
  • Functional Recovery
  • Drug Intervention

Interventions

DRUG

Roflumilast Oral Tablet

Once daily for 12 weeks

Sponsors & Collaborators

  • Netherlands Brain Foundation

    collaborator OTHER

  • Maastricht University

    lead OTHER

Principal Investigators

  • Ieke Winkens, Dr. · Assistant Professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04854811 on ClinicalTrials.gov